Home / News
Regulatory decisions, safety alerts, NHS access changes and trial results, dated and sourced. Newest first. No opinion pieces, no product launches presented as news, and negative trial results recorded the same as positive ones.
A tablet form of semaglutide, branded Wegovy, went on sale in the UK on 6 July, the first GLP-1 medicine available as a pill rather than an injection. The MHRA approved it a month earlier. A National Pharmacy Association survey published on launch day reported that around three-quarters of pharmacies expected to start significant numbers of eligible patients on it.
Two manufacturers have filed abbreviated new drug applications for generic tirzepatide. Acceptance of a filing is not approval, and the originator holds patents running to 2036, so this does not mean cheaper tirzepatide is imminent in the UK or anywhere else.
Results from the STEP UP trial reported greater average weight loss at a higher semaglutide dose than the currently licensed maximum. A trial result is not a licence: any change to approved dosing requires a regulatory submission and assessment first.
The SOUL trial reported a reduction in major adverse cardiovascular events among adults with type 2 diabetes at high cardiovascular risk. Cardiovascular outcome trials matter more than weight figures for judging long-term benefit, and they take years to run.
The EVOKE and EVOKE+ trials, enrolling over 3,800 people across two years, found no difference in Alzheimer's disease progression. This is worth recording precisely because it is a negative result. GLP-1 drugs have been widely speculated about for conditions well beyond diabetes and weight, and most of those hypotheses will fail.
An investigative report published in June, alongside reported MHRA enforcement activity in the UK and a sharp rise in poison centre contacts in the United States, brought fresh attention to unlicensed retatrutide sold online. Retatrutide has no marketing authorisation in any country and cannot be lawfully supplied for human use.
The FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances that outsourcing facilities may compound, on the basis that there is no clinical need. This is a US matter with no direct UK effect, but compounded product from US sources has been a route into the UK grey market.
The MHRA began investigating UK clinics making therapeutic claims about unregulated peptide products. BPC-157 was reported as the first compound named. The regulator's stated position is that the products are unlicensed and the marketing has run ahead of the evidence.
Guidance covering implementation of NICE TA1026 for tirzepatide in obesity was published, setting out the requirement for wrap-around care alongside prescribing. NICE guidance effectively mandates that support, so tirzepatide is not funded as a standalone treatment.
From 1 April, prescribing of tirzepatide for obesity was incorporated into the 2026/27 GP contract through new Quality and Outcomes Framework indicators. Participation by practices is optional, so meeting the eligibility criteria does not guarantee access, and availability varies by area.
The MHRA issued an alert about falsified 15 mg Mounjaro KwikPens in circulation. Product bought anywhere other than a registered pharmacy cannot be verified as containing what the label states.
The MHRA issued a drug safety alert and updated product information for GLP-1 medicines to highlight acute pancreatitis as a known but infrequent side effect that can be fatal. Patients were advised to be alert to severe, persistent stomach pain that may spread to the back, with nausea or vomiting. Anyone experiencing that should seek medical attention rather than wait.
What counts as news here
Included: MHRA licensing decisions and safety alerts, NICE appraisals and criteria changes, NHS access and commissioning changes, published trial results including negative ones, enforcement action, and counterfeit warnings.
Excluded: price changes and promotions, clinic and pharmacy announcements, anything sourced only to a company press release, and preliminary figures released by announcement rather than publication. Where an item is still awaiting a check against its primary source, it says so on the item.